ImmuPharma plc (LON:IMM – Get Free Report) shot up 7.5% during trading on Monday . The stock traded as high as GBX 1.32 ($0.02) and last traded at GBX 1.32 ($0.02). 1,167,245 shares were traded during trading, a decline of 34% from the average session volume of 1,776,601 shares. The stock had previously closed at GBX 1.23 ($0.02).
ImmuPharma Price Performance
The company has a market cap of £5.50 million, a PE ratio of -122.80 and a beta of 1.53. The stock’s 50-day moving average is GBX 1.72 and its 200 day moving average is GBX 1.85.
About ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
See Also
- Five stocks we like better than ImmuPharma
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Analog Devices: Why the Uptrend Could Accelerate in 2025
- Top Stocks Investing in 5G Technology
- Texas Pacific Land: Permian Basin Powerhouse With an AI Edge
- Comparing and Trading High PE Ratio Stocks
- ServiceNow: Will the High-Flyer Finally Split in 2024?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.